Skip to main content

Advertisement

SpringerLink
Log in

Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Aim

Differentiated thyroid cancer is characterized by a very good prognosis in the majority of the patients. The therapy of choice is surgery followed by ablation with Iodine-131 (I-131). However, some patients have metastases that have lost the capability of concentrating I-131, even when it is given in therapeutic doses. In the present study, we describe the value of Indium-111 Octreotide (Octreoscan) in differentiated thyroid cancer patients with increased Tg levels who failed to demonstrate a response to treatment with high-dose I-131.

Method

Fifteen consecutive patients with progressive differentiated thyroid cancer (ten female, five male) (mean age: 59 years, range 13–81 years; eight papillary, six follicular, and one Hürthle cell carcinoma) were studied. Progression was based on increasing Tg levels and was confirmed by radiological evaluation. Whole body scintigraphy (WBS) was performed after the administration of 200 MBq of Indium-111-Octreotide. The images were assessed by two experienced observers and compared with post-treatment I-131 WBS.

Results

In seven out of 15 patients distant metastases were already present at initial stage, whereas in ten patients the primary tumor stage was T3 or T4 indicating that the majority of the patients had advanced disease. In two out of five patients with a positive I-131 WBS, Indium-111-Octreotide was false negative. In nine out of ten patients with a negative I-131 WBS, Indium-111-Octreotide demonstrated multiple metastases. In those patients with a positive SSR-scintigraphy, metastases were found in the lungs (n=14), bone (n=7), mediastinum (n=3), liver (n=2), brains (n=1), and cutis (n=1). Overall, three out of 15 patients had a negative Indium-111-Octreotide result revealing a sensitivity of 80%.

Conclusion

Our findings demonstrate the diagnostic value of Indium-111-Octreotide in differentiated thyroid cancer that fails to respond to I-131 treatment. It opens the possibility for additional treatment with high doses of Indium-111-Octreotide or its analogs in a majority of the patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1. A

Similar content being viewed by others

References

  • Ain KB, Taylor KD, Tofiq S, Venkataraman G (1997) Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 82:1857–1862

    Google Scholar 

  • Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C (1996) Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 81:2541–2544

    CAS  PubMed  Google Scholar 

  • Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, Enkaoua E, Turpin G, Chiras J, Saillant G, Hejblum G (2001) Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86:1568–1573

    CAS  PubMed  Google Scholar 

  • Brendel AJ, Guyot M, Jeandot R, Lefort G, Manciet G (1988) Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma. J Nucl Med 29:1515–1520

    Google Scholar 

  • Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME, Busnardo B (1993) Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 34:1626–1631

    CAS  PubMed  Google Scholar 

  • de Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ, Kooij PP, van Gameren A, Krenning EP (2001) Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 42:1841–1846

    Google Scholar 

  • de Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32:133–140

    Article  PubMed  Google Scholar 

  • Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H (1998) Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm? Nuklearmedizin 37:12–17

    Google Scholar 

  • Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W (1996) Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37:1468–1472

    CAS  PubMed  Google Scholar 

  • Forssell-Aronsson EB, Nilsson O, Bejegard SA, Kolby L, Bernhardt P, Molne J, Hashemi SH, Wangberg B, Tisell LE, Ahlman H (2000) 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 41:636–642

    Google Scholar 

  • Garin E, Devillers A, Le Cloirec J, Bernard AM, Lescouarc'h J, Herry JY, Reubi JC, Bourguet P (1998) Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur J Nucl Med 25:687–694

    Google Scholar 

  • Görges R, Kahaly G, Muller-Brand J, Macke H, Roser HW, Bockisch A (2001) Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 11:647–659

    Article  PubMed  Google Scholar 

  • Grunwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, Palmedo H, Ruhlmann J, Kozak B, Biersack HJ (1996) Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23:312–319

    Google Scholar 

  • Haslinghuis LM, Krenning EP, de Herder WW, Reijs AE, Kwekkeboom DJ (2001) Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 24:415–422

    CAS  PubMed  Google Scholar 

  • Haugen BR (1999) Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 16:34–41

    Article  CAS  PubMed  Google Scholar 

  • Hoelting T, Duh QY, Clark OH, Herfarth C (1996) Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo. J Clin Endocrinol Metab 81:2638–2641

    CAS  PubMed  Google Scholar 

  • Krenning EP, Kooij PP, Pauwels S, Breeman WA, Postema PT, de Herder WW, Valkema R, Kwekkeboom DJ (1996) Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 57[Suppl 1]:57–61

  • Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, Jamar F, Pauwels S, Valkema R (1999) Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 10[Suppl 2]: S23-S29

  • Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S, Schlumberger M (1999) Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84:3228–3234

    Google Scholar 

  • Lin JD, Kao PF, Weng HF, Lu WT, Huang MJ (1998) Relative value of thallium-201 and iodine-131 scans in the detection of recurrence or distant metastasis of well differentiated thyroid carcinoma. Eur J Nucl Med 25:695–700

    Google Scholar 

  • Lorberboym M, Murthy S, Mechanick JI, Bergman D, Morris JC, Kim CK (1996) Thallium-201 and iodine-131 scintigraphy in differentiated thyroid carcinoma. J Nucl Med 37:1487–1491

    Google Scholar 

  • Maxon HR (1999) Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med 43:313–323

    Google Scholar 

  • McCarthy KE, Woltering EA, Anthony LB (2000) In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives. Q J Nucl Med 44:88–95

    CAS  PubMed  Google Scholar 

  • Miyamoto S, Kasagi K, Misaki T, Alam MS, Konishi J (1997) Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma. J Nucl Med 38:352–356

    Google Scholar 

  • Nakada K, Katoh C, Kanegae K, Tsukamoto E, Shiga T, Mochizuki T, Itoh K, Tamaki N (1998) Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma. J Nucl Med 39:807–810

    CAS  PubMed  Google Scholar 

  • Nemec J, Nyvltova O, Blazek T, Vlcek P, Racek P, Novak Z, Preiningerova M, Hubackova M, Krizo M, Zimak J, Bilek R (1996) Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med 23:69–71

    Google Scholar 

  • Pachucki J, Burmeister LA (1997) Evaluation and treatment of persistent thyroglobulinemia in patients with well-differentiated thyroid cancer. Eur J Endocrinol 137:254–261

    CAS  PubMed  Google Scholar 

  • Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B (1998) FDG accumulation and tumor biology. Nucl Med Biol 25:317–322

    Article  CAS  PubMed  Google Scholar 

  • Postema PT, de Herder WW, Reubi JC, Oei HY, Kwekkeboom DJ, Bruining HJ, Bonjer J, van Toor H, Hennemann G, Krenning EP (1996) Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion 57[Suppl 1]:36–37

  • Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273–282

    CAS  PubMed  Google Scholar 

  • Reubi JC, Waser B, Schaer JC, Laissue JA (2001) Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836–846

    CAS  PubMed  Google Scholar 

  • Robbins RJ, Hill RH, Wang W, Macapinlac HH, Larson SM (2000) Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 10:177–183

    CAS  PubMed  Google Scholar 

  • Roelants V, Nayer PD, Bouckaert A, Beckers C (1997) The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24:722–727

    Article  CAS  PubMed  Google Scholar 

  • Rubello D, Saladini G, Carpi A, Casara D (2000a) Nuclear medicine imaging procedures in differentiated thyroid carcinoma patients with negative iodine scan. Biomed Pharmacother 54:337–344

    Article  CAS  PubMed  Google Scholar 

  • Rubello D, Mazzarotto R, Casara D (2000b) The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. Eur J Nucl Med 27:431–440

    CAS  PubMed  Google Scholar 

  • Rubello D, Piotto A, Pagetta C, Pelizzo MR, Casara D (2002) (99m)Tc-MIBI radio-guided surgery for recurrent thyroid carcinoma: technical feasibility and procedure, and preliminary clinical results. Eur J Nucl Med Mol Imaging 29:1201–1205

    Google Scholar 

  • Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338:297–306

    CAS  PubMed  Google Scholar 

  • Schlumberger M, Baudin E (1998) Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 138:249–252

    CAS  PubMed  Google Scholar 

  • Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, Peck-Radosavljevic M, Hamilton G, Kaserer K, Kofler A, Schlangbauer-Wadl H, Traub T, Virgolini I (1999) DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 140:5136–5148

    CAS  PubMed  Google Scholar 

  • Stokkel MP, de Klerk JH, Zelissen PM, Koppeschaar HP, van Rijk PP (1999) Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results. Eur J Nucl Med 26:1606–1609

    Article  CAS  PubMed  Google Scholar 

  • Sundram FX, Goh AS, Ang ES (1993) Role of technetium-99m sestamibi in localisation of thyroid cancer metastases. Ann Acad Med Singapore 22:557–559

    CAS  PubMed  Google Scholar 

  • Uematsu H, Sadato N, Ohtsubo T, Tsuchida T, Nakamura S, Sugimoto K, Waki A, Takahashi N, Yonekura Y, Tsuda G, Saito H, Hayashi N, Yamamoto K, Ishii Y (1998) Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. J Nucl Med 39:453–459

    Google Scholar 

  • van den Brekel MW (2000) Lymph node metastases: CT and MRI. Eur J Radiol 33:230–238

    Article  PubMed  Google Scholar 

  • van den Brekel MW, Castelijns JA (2000) Imaging of lymph nodes in the neck. Semin Roentgenol 35:42–53

    PubMed  Google Scholar 

  • Van Wyngaarden KE, Pauwels EK (1995) Fluorodeoxyglucose (FDG) and tumor metabolism. Nucl Med Commun 16:987–989

    PubMed  Google Scholar 

  • Vassilopoulou-Sellin R (2001) Long-term outcome of children with papillary thyroid cancer. Surgery 129:769

    Article  CAS  Google Scholar 

  • Vassilopoulou-Sellin R, Schultz PN, Haynie TP (1996) Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 78:493–501

    Article  CAS  PubMed  Google Scholar 

  • Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Andreae F, Kurtaran A, Dudczak R (2001) New trends in peptide receptor radioligands. Q J Nucl Med 45:153–159

    Google Scholar 

  • Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Burggasser G, Andreae F, Kurtaran A, Dudczak R (2002) Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 8:1781–1807

    CAS  PubMed  Google Scholar 

  • Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ (2000) Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85:1107–1113

    CAS  PubMed  Google Scholar 

  • Weckbecker G, Liu R, Tolcsvai L, Bruns C (1992) Antiproliferative effects of the somatostatin analogue octreotide (SMS 201–995) on ZR-75–1 human breast cancer cells in vivo and in vitro. Cancer Res 52:4973–4978

    CAS  PubMed  Google Scholar 

  • Weckbecker G, Raulf F, Tolcsvai L, Bruns C (1996) Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo. Digestion 57[Suppl 1]:22–28

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Leiden University Medical Center, P.O. Box 9600, 2300, RC Leiden, The Netherlands

    Marcel P. M. Stokkel, Henna I. E. Reigman & Robbert B. T. Verkooijen

  2. Department of Endocrinology and Metabolic Disorders, Leiden University Medical Center, Leiden, The Netherlands

    Jan W. Smit

Authors
  1. Marcel P. M. Stokkel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henna I. E. Reigman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robbert B. T. Verkooijen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jan W. Smit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcel P. M. Stokkel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stokkel, M.P.M., Reigman, H.I.E., Verkooijen, R.B.T. et al. Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131. J Cancer Res Clin Oncol 129, 287–294 (2003). https://doi.org/10.1007/s00432-003-0435-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-003-0435-9

Keywords

Search

Navigation